Published endocrinology research describes GLP-1 as involved in appetite-related signaling , insulin secretion pathways, and gastric emptying
The primary antibodies used are as follows: anti-ABCA1 (1:500, ab18180, Abcam, Cambridge, United Kingdom), anti-PARP-1 (1:1000, 13371-1-AP, Proteintech, Wuhan, China), anti-p-PARP-1 (1:1000, MBS9206900, MyBioSource, San Diego, CA, United States), anti-LXR (1:500, ab176323, Abcam), anti-AMPK (1:1000, 10929-2-AP, Proteintech), anti-p-AMPK (1:1000, ab133448, Abcam)
GLP-1 receptor agonists are FDA-approved for two primary indications: type 2 diabetes management and chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity
ICER gave semaglutide and tirzepatide their highest value rating for obesity vs diet alone